Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Analysts at Svb Leerink lifted their FY2022 earnings per share estimates for shares of Jazz Pharmaceuticals in a research report issued on Tuesday, November 5th. Svb Leerink analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings per share of $25.40 for the year, up from their previous forecast of $25.33. Svb Leerink also issued estimates for Jazz Pharmaceuticals’ FY2023 earnings at $21.22 EPS.
A number of other equities analysts have also weighed in on the stock. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, August 12th. Oppenheimer set a $176.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, September 26th. TheStreet lowered shares of Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, October 18th. Piper Jaffray Companies lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $205.00 to $142.00 in a research note on Wednesday, August 21st. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $165.71.
JAZZ stock traded up $4.18 during trading on Friday, hitting $130.14. The company had a trading volume of 747,500 shares, compared to its average volume of 551,936. The stock has a market cap of $7.24 billion, a price-to-earnings ratio of 10.63, a PEG ratio of 1.57 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 3.71 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a 12 month low of $113.52 and a 12 month high of $154.44. The firm has a 50-day moving average price of $124.77 and a 200-day moving average price of $131.70.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The firm had revenue of $537.70 million during the quarter, compared to analysts’ expectations of $523.92 million. During the same quarter in the previous year, the company posted $3.58 EPS. Jazz Pharmaceuticals’s revenue was up 14.6% on a year-over-year basis.
Several institutional investors have recently bought and sold shares of JAZZ. Denali Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $584,000. WINTON GROUP Ltd lifted its stake in Jazz Pharmaceuticals by 218.8% in the 2nd quarter. WINTON GROUP Ltd now owns 4,942 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 3,392 shares during the last quarter. Centric Wealth Management acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $884,000. Xact Kapitalforvaltning AB lifted its stake in Jazz Pharmaceuticals by 10.3% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 14,922 shares of the specialty pharmaceutical company’s stock valued at $2,127,000 after purchasing an additional 1,389 shares during the last quarter. Finally, CENTRAL TRUST Co lifted its stake in Jazz Pharmaceuticals by 256.4% in the 2nd quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 1,095 shares during the last quarter. Institutional investors own 87.71% of the company’s stock.
In other news, SVP Paul Treacy sold 4,371 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. Following the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at $40,541,150. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,371 shares of company stock valued at $730,575. Company insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: What is Forex?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.